Posted 30th August 2019 by Liv Sewell
NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.
Posted 8th April 2019 by Joshua Sewell
The human gut is a complex ecosystem dominated by bacteria and their viruses, i.e. phages. Approximately half of the viruses that reside in our intestine are derived from lysogens, bacteria that contain normally dormant viruses – prophages — in their genome.
Posted 27th February 2019 by Joshua Sewell
Professor Margaret Morris is Chair and Head of Pharmacology, School of Medical Sciences, University of NSW. Her research explores the underlying brain mechanisms in epilepsy, obesity, diabetes, and the link between obesity and high blood pressure. We recently asked her about her research into obesity and the microbiome.
Posted 27th December 2017 by Jane Williams
Defined health outcomes are increasingly being linked to prebiotic ingredients and supplements. For example, mounting evidence recently led the FDA to issue a qualified health claim regarding the ability of digestion resistant starch to reduce the risk of type 2 diabetes. With the direct annual cost of diabetes recently estimated to be $825B (1), the potential application of prebiotics to reduce disease risk is appealing from both health care and business investment perspectives.